34 drug operating companies meet or basically meet GSP compliance supervision and inspection

 On December 22, 2021, the Guangdong Provincial Drug Administration website issued a notice on the supervision and inspection of drug distribution (No.
100 of 2021), and 34 drug distributors met or basically met the GSP compliance supervision and inspection
.
According to the announcement, in accordance with the "Pharmaceutical Business Quality Management Regulations", "Drug Inspection Management Measures (Trial)" and other relevant regulations, the bureau organized investigations against Guangdong Yuekang Pharmaceutical Co.
, Ltd.
, Tianfangjian (China) Pharmaceutical Co.
, Ltd.
, and Shanghai Pharmaceutical Holdings Guangdong Co.
, Ltd.
, Guangdong Wannianqing Pharmaceutical Co.
, Ltd.
, Guangdong Huajian Medical Equipment Co.
, Ltd.
, Guangdong Yifeng Yili Kangxin Pharmacy Chain Co.
, Ltd.
, Guangzhou Baiyunshan Pharmaceutical Sales Co.
, Ltd.
and 34 pharmaceutical companies have carried out drug management quality management standards ( GSP) conformity supervision and inspection, and the comprehensive assessment conclusions are in conformity and basic conformity are announced
.
Serial number company name drug business license inspection time comprehensive evaluation conclusion 1 Guangdong Yuekang Pharmaceutical Co.
, Ltd.
Guangdong AA7560758 November 26-27, 2021 Compliant with 2 days Fangjian (China) Pharmaceutical Co.
, Ltd.
Guangdong AA0201697 November 26-27, 2021 Japan conforms to 3 Shanghai Pharmaceuticals Holdings Guangdong Co.
, Ltd.
Guangdong AA0200685
.
After years of development, the company has covered the entire industrial chain of high-end chemical drug R&D, production and sales, established a business system that integrates raw materials and preparations and imitations, and accelerates the development of the layout in the field of innovative drugs
.
Yuekang Pharmaceutical is product-oriented, attaches great importance to product research and development and industrialization, and has formed a rich product line with a variety of dosage forms such as injections, freeze-dried powder injections, tablets, capsules and other chemical raw materials
.
The diversified product line has enabled Yuekang Pharmaceutical to have multiple sources of profit, which has brought continuous growth in profitability
.
The third-quarter report shows that in the first three quarters of 2021, Yuekang Pharmaceutical achieved a year-on-year increase of 19.
26% in operating income to 3.
345 billion yuan.
The net profit attributable to shareholders of listed companies increased by 47.
07% year-on-year to 374 million yuan, and non-net profit was deducted.
A year-on-year increase of 63.
75% was 354 million yuan
.
Guangzhou Baiyunshan Pharmaceutical Sales Co.
, Ltd.
is a wholly-owned subsidiary of Guangzhou Pharmaceutical Group.
Relying on the strong R&D and production advantages of Guangzhou Pharmaceutical Group, the company integrates the The three strong brands of "Xiutang"
.
The company has established a flat marketing structure, determined to innovate its operating mechanism, focused on improving the quality of operations, gave full play to its integrated advantages, and continuously improved its marketing network and management system
.